Latigo Biotherapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 15.54 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.03B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly k...